{
    "clinical_study": {
        "@rank": "15153", 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and effectiveness of two different\n      formulations of an HIV vaccine in infants born to HIV-infected women."
        }, 
        "brief_title": "Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Infants may be eligible for this study if they:\n\n          -  Are 1 to 3 days old."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "3 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000809", 
            "org_study_id": "ACTG 279", 
            "secondary_id": "11255"
        }, 
        "intervention": [
            {
                "intervention_name": "Aluminum hydroxide", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "QS-21", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "MN rsgp120/HIV-1", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aluminum Hydroxide", 
                "QS 21"
            ]
        }, 
        "keyword": [
            "HIV Preventive Vaccine", 
            "HIV Therapeutic Vaccine"
        ], 
        "lastchanged_date": "May 16, 2012", 
        "official_title": "A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000809"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {}
}